by Truveta staff | May 11, 2026 | Research
Researchers from Rutgers New Jersey Medical School, Fisher Clinical Research Institute, and Stanford University School of Medicine examined stroke risk after ischemic ocular events in 11,297 adults Within one year of the ocular event, 22.8% experienced ischemic stroke...
by Truveta staff | Apr 23, 2026 | Research
A CDC-led study published in the American Journal of Preventive Medicine used linked electronic health records and pharmacy dispensing data from Truveta to analyze 4,027,607 antihypertensive prescriptions among 936,502 US adults with hypertension. Compared with 7 am...
by Truveta staff | Apr 21, 2026 | Research
Authors: Wilson Lau ⊕Truveta, Inc, Bellevue, WA, Youngwon Kim ⊕Truveta, Inc, Bellevue, WA, Sravanthi Parasa ⊕Swedish Medical Center, Seattle, WA, Md Enamul Haque ⊕Truveta, Inc, Bellevue, WA, Anand Oka ⊕Truveta, Inc, Bellevue, WA, Jay Nanduri ⊕Truveta, Inc, Bellevue,...
by Truveta Research | Apr 20, 2026 | Research
Nearly 8% of all prescriptions in March 2026 were for GLP-1 RAs, following the largest quarter-over-quarter percentage point increase in overall GLP-1 RA prescribing observed since the study began in 2019. First-time anti-obesity medication (AOM) prescribing increased...
by Truveta Research | Apr 14, 2026 | Research
Authors: Karen G Farrar ⊕University of Southern California, Los Angeles, CA, Duy Do ⊕Truveta, Inc, Bellevue, WA, Nina B Masters ⊕Truveta, Inc, Bellevue, WA, Brianna M Cartwright ⊕Truveta, Inc, Bellevue, WA After CVS Caremark made anti-obesity semaglutide the preferred...
by Truveta Research | Apr 14, 2026 | Research
Authors: Brianna M Cartwright ⊕Truveta, Inc, Bellevue, WA, Duy Do ⊕Truveta, Inc, Bellevue, WA, Jennifer J Liang ⊕Truveta, Inc, Bellevue, WA, Natasha Geogy ⊕Truveta, Inc, Bellevue, WA, Nina B Masters ⊕Truveta, Inc, Bellevue, WA, Karen G Farrar ⊕Truveta, Inc, Bellevue,...
